



Our STN: BL 125563/0

BLA APPROVAL

MCM Vaccine Company
Attention: Michael F. Stirr
Sanofi Pasteur Inc
Discovery Drive
Swiftwater, PA 18370-0187

December 21, 2018

Dear Mr. Stirr:

Please refer to your Biologics License Application (BLA) for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine dated August 13, 2014, received on August 13, 2014, submitted under section 351(a) of the Public Health Service Act (PHS Act).

LICENSING

We are issuing Department of Health and Human Services U.S. License No. 2007 to MCM Vaccine Company, Swiftwater, Pennsylvania under the provisions of section 351(a) of the PHS Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine, which is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to *Haemophilus influenzae* type b.

You may label your product with the proprietary name VAXELIS™ and market it in a 0.5 mL single dose vial in packages of 10 vials.

The review of this product was associated with the following National Clinical Trial (NCT) number(s): NCT00551629, NCT00551915, NCT00362427, NCT01337167 and NCT01340937.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture VAXELIS™ drug substances as follows: *Haemophilus influenzae* b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] at the Merck Sharp and Dohme Corp. facility located at (b) (4); Inactivated Poliovirus at the Sanofi Pasteur (b) (4) facility located at (b) (4); and Acellular Pertussis, diphtheria and tetanus toxoid at the Sanofi Pasteur Limited facility located at 1755 Steeles Avenue West, Toronto, Ontario, Canada. The final formulated product will be manufactured, filled, labeled and packaged at the Sanofi Pasteur Limited facility located at 1755 Steeles Avenue West, Toronto, Ontario, Canada.

We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.

DATING PERIOD

The dating period for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, *Haemophilus* b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine shall be 48 months from the date of manufacture when stored at 2°C to 8°C. The date of manufacture shall be defined as the date of final bulk product formulation.

FDA LOT RELEASE

Please submit samples of the product in final containers together with protocols showing results of all applicable tests. You may not distribute any lots of product until you receive a notification of release from the Director, Center for Biologics Evaluation and Research (CBER).

BIOLOGICAL PRODUCT DEVIATIONS

You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packaging, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to the Director, Office of Compliance and Biologics Quality, at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

MANUFACTURING CHANGES

You must submit information to your BLA for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine, or in the manufacturing facilities.

LABELING

We hereby approve the draft package insert labeling submitted under amendment 57, dated December 17, 2018, and the draft carton and container labeling submitted under amendment 55, dated December 07, 2018.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

PACKAGE AND CONTAINER LABELS

Please electronically submit final printed package and container labels that are identical to the package and container labels submitted on December 07, 2018, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at <https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm333969.pdf>.

All final labeling should be submitted as Product Correspondence to this BLA 125563 at the time of use (prior to marketing) and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

ADVERSE EVENT REPORTING

You must submit adverse experience reports in accordance with the adverse experience reporting requirements for licensed biological products (21 CFR 600.80), and you must submit distribution reports as described in 21 CFR 600.81. For information on adverse experience reporting, please refer to the guidance for industry *Providing Submissions in Electronic Format – Postmarketing Safety Reports for Vaccines* at <http://www.fda.gov/forindustry/electronicsubmissiongateway/ucm387293.htm>. For information on distribution reporting, please refer to the guidance for industry *Electronic Submission of Lot Distribution Reports* at <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm061966.htm>.

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages less than six weeks and for ages five through 17 years because the product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in these age groups and is not likely to be used in a substantial number of pediatric patients in these groups.

We note that you have fulfilled the pediatric study requirement for ages 6 weeks through 4 years (before 5th birthday) for this application.

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biological products qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

POST APPROVAL FEEDBACK MEETING

New biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, please contact the Regulatory Project Manager for this application.

REFERENCE PRODUCT DESIGNATION AND REQUEST FOR EXCLUSIVITY

We acknowledge your request for a date of first licensure (reference product exclusivity) as described under section 351(k)(7) of the PHS Act for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine.

We are reviewing the relevant information including the information you provided and will notify you of our decision post approval.

Sincerely,

Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

Marion Gruber, Ph.D.
Director
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research